• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Haematol . Trajectories of the SARS-CoV-2 RNA load in patients with haematological malignancy

tetano

Editor, Senior Moderator
Eur J Haematol


. 2023 Mar 25.
doi: 10.1111/ejh.13967. Online ahead of print.
Trajectories of the SARS-CoV-2 RNA load in patients with haematological malignancy


Satoshi Mitsuyuki[SUP] 1 [/SUP], Masashi Nishikubo[SUP] 1 [/SUP], Yoshimitsu Shimomura[SUP] 1 2 [/SUP], Yukie Ohyama[SUP] 3 [/SUP], Hayato Maruoka[SUP] 3 [/SUP], Seiko Nasu[SUP] 3 [/SUP], Tomoyo Kubo[SUP] 1 [/SUP], Yuta Suzuki[SUP] 1 [/SUP], Naoki Okada[SUP] 1 [/SUP], Daishi Nakagawa[SUP] 1 [/SUP], Kimimori Kamijo[SUP] 1 [/SUP], Ryusuke Yamamoto[SUP] 1 [/SUP], Yuya Nagai[SUP] 1 [/SUP], Nobuhiro Hiramoto[SUP] 1 [/SUP], Satoshi Yoshioka[SUP] 1 [/SUP], Noboru Yonetani[SUP] 1 [/SUP], Kohei Hasegawa[SUP] 4 [/SUP], Hirokazu Kuroda[SUP] 4 [/SUP], Toshikazu Hasuike[SUP] 4 [/SUP], Asako Doi[SUP] 4 [/SUP], Tadakazu Kondo[SUP] 1 [/SUP], Takayuki Ishikawa[SUP] 1 [/SUP]



Affiliations

Abstract

Objectives: The higher risk of prolonged viral shedding in coronavirus disease (COVID-19) patients with haematological malignancies (HM) necessitates test-based de-isolation strategies. However, evidence to establish their appropriate isolation period is insufficient. This study investigated the factors affecting prolonged viral shedding and the requisite isolation period in these patients.
Methods: We retrospectively reviewed 14 COVID-19 patients with HM between January and April 2022, who were subjected to our test-based de-isolation strategy, followed by analysis of the viral load trajectory. The viral loads of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were evaluated using the cycle threshold (Ct) of the reverse-transcription quantitative polymerase chain reaction. The trajectories were classified according to the time-interval from COVID-19 onset to attainment of Ct values >30.
Results: The median interval between onset and attainment of a Ct value >30 was 22 days. Five patients with mild or moderate COVID-19 without intense treatment histories achieved Ct values >30 within 20 days. The other nine patients needed more than 20 days, including three patients who did not meet this criterion during the observation period.
Conclusions: The SARS-CoV-2 viral load trajectories in patients with HM can be stratified by treatment history for the underlying HM and severity of COVID-19. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; SARS-CoV-2; Virus Shedding.
 
Back
Top Bottom